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Abstract
Background: Tafenoquine is an 8-aminoquinoline being developed for radical cure (blood and liver stage
elimination) of Plasmodium vivax. During monotherapy treatment, the compound exhibits slow parasite and fever
clearance times, and toxicity in glucose-6-phosphate dehydrogenase (G6PD) deficiency is a concern. Combination
with other antimalarials may mitigate these concerns.
Methods: In 2005, the radical curative efficacy of tafenoquine combinations was investigated in Plasmodium
cynomolgi-infected naïve Indian-origin Rhesus monkeys. In the first cohort, groups of two monkeys were treated
with a three-day regimen of tafenoquine at different doses alone and in combination with a three-day chloroquine
regimen to determine the minimum curative dose (MCD). In the second cohort, the radical curative efficacy of a
single-day regimen of tafenoquine-mefloquine was compared to that of two three-day regimens comprising
tafenoquine at its MCD with chloroquine or artemether-lumefantrine in groups of six monkeys. In a final cohort,
the efficacy of the MCD of tafenoquine against hypnozoites alone and in combination with chloroquine was
investigated in groups of six monkeys after quinine pre-treatment to eliminate asexual parasites. Plasma
tafenoquine, chloroquine and desethylchloroquine concentrations were determined by LC-MS in order to compare
doses of the drugs to those used clinically in humans.
Results: The total MCD of tafenoquine required in combination regimens for radical cure was ten-fold lower
(1.8 mg/kg versus 18 mg/kg) than for monotherapy. This regimen (1.8 mg/kg) was equally efficacious as
monotherapy or in combination with chloroquine after quinine pre-treatment to eliminate asexual stages. The
same dose of (1.8 mg/kg) was radically curative in combination with artemether-lumefantrine. Tafenoquine
was also radically curative when combined with mefloquine. The MCD of tafenoquine monotherapy for
radical cure (18 mg/kg) appears to be biologically equivalent to a 600-1200 mg dose in humans. At its MCD
in combination with blood schizonticidal drugs (1.8 mg/kg), the maximum observed plasma concentrations
were substantially lower than (20-84 versus 550-1,100 ng/ml) after administration of 1, 200 mg in clinical
studies.
Conclusions: Ten-fold lower clinical doses of tafenoquine than used in prior studies may be effective against P.
vivax hypnozoites if the drug is deployed in combination with effective blood-schizonticidal drugs.
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Tafenoquine has potential to be a very important tool in
malaria elimination efforts. The 8-aminoquinoline class
is the only class that kills key survival stages of the para-
site - Plasmodium vivax hypnozoites and stage 5 Plas-
modium falciparum gametocytes. It is currently in Phase
II/III clinical trials for the radical cure of P. vivax
malaria, in a one-day regimen as a consequence of its
long half-life [1]. In two recent case reports, tafenoquine
was administered alone to two patients with acute P.
vivax malaria instead of the normal sequential combina-
tion of chloroquine (1500 mg over three days) and pri-
maquine (420 mg over 14 days, [2]). No relapses or
recrudescences were observed in these two cases. How-
ever, parasite clearance times (approximately 84 h) were
longer than those observed for typical blood schizontici-
dal drugs. Tafenoquine, like other 8-aminoquinolines
such as primaquine, induced haemolytic anaemia in
individuals with glucose-6-phosphate dehydrogenase
(G6PD) deficiency [3,4]. Human studies to assess this
risk are on-going.
Appropriate combination of tafenoquine with a more
potent and fast acting blood schizonticidal drug (effec-
tive against blood-stage malarial parasites) has the
potential to yield a more rapidly acting regimen. Also, if
such combination allowed the dose of tafenoquine
required for radical cure to be reduced, its haemolytic
toxicity at therapeutic doses could be mitigated. Chloro-
quine, mefloquine, artemether-lumefantrine and other
forms of artemisinin-based combination therapy (ACT)
would be logical blood schizonticidal partner drugs.
Chloroquine is already the standard cure for blood-stage
treatment of symptomatic P. vivax malaria in many
parts of the world. The combination of tafenoquine and
chloroquine is synergistic against chloroquine-resistant
P. vivax in Aotus monkeys [5]). Mefloquine and pipera-
quine would be good pharmacokinetic matches for tafe-
noquine based on their long half-lives [6]. ACT offers
an advantage over mefloquine and chloroquine due to
its activity against drug-resistant P. falciparum [7].
There is not currently an animal model of P. vivax
available to evaluate the effects of drugs on the blood
and liver stages of P. vivax.T r a d i t i o n a l l y ,t h ePlasmo-
dium cynomolgi-Rhesus monkey relapsing malaria
m o d e l[ 8 , 9 ]h a sb e e nu s e da sas u r r o g a t ea n dh a sb e e n
predictive of effects for the human P. vivax treatment.
The USAMC-AFRIMS first used the Indian-origin Rhe-
sus monkey/P. cynomolgi malaria model for anti-malarial
drug testing in 1975 [10]. The infection is detected read-
ily by visualizing the parasites on blood smears. Rhesus
monkeys develop parasitaemia to a greater magnitude
and uniformity than cynomolgus monkeys which
demonstrated self cure [11]. Rhesus monkeys with an
intact spleen usually tolerate the infection very well and
show no signs of clinical illness. This model is an
important tool in the development of drugs to treat P.
vivax malaria.
In this study, this model was utilized to determine
whether the monotherapy dose of tafenoquine required
for radical cure could be reduced by combination with
chloroquine. The utility of mefloquine, atovaquone-pro-
guanil and artemether-lumefantrine as partner drugs for
tafenoquine was also assessed relative to chloroquine.
Methods
The United States Army Medical Component, Armed
Forces Research Institute of Medical Sciences (USAMC-
AFRIMS) Institutional Animal care and Use Committee
(IACUC) and the Animal Use Review Division, U.S.
Army Medical Research and Materiel Command
reviewed and approved these studies. Animals were
maintained in accordance with established principles
under the G u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r y
Animals [12]. The USAMC-AFRIMS animal care and
use programme has been considered an exemplary
accredited programme by Association for Assessment
and Accreditation for Laboratory Animal Care (AAA-
LAC) International.
General methods
The radical curative effects of the drugs were evaluated
in three cohorts 20, 20 and 14 P. cynomolgi-bastianelli-
infected Macaca mulatta (captive bred, Indian origin,
male or female, 3-6 kg, 2-4 years old, specific pathogen
free, Rhesus monkeys) using methods described pre-
viously by Schmidt et al [8] and others [9,13-15], with
the following minor adjustments from Corcoran [14] in
place since 2005: (i) the use of monkey plasma to dilute
the sporozoite suspension prior to iv inoculation was
discontinued (ii) phosphate-buffered saline (PBS) was
used to dilute the final sporozoites preparation and this
was later supplemented with 5% bovine serum albumin,
(iii) phase-contrast microscopy was used to quantify
active sporozoites from freshly harvested mosquito sali-
vary gland suspension rather than lengthy staining
methods, and (iv) the inoculum was standardized as a
single intravenous injection of one million sporozoites
per monkey. The sporozoites were obtained from sali-
vary gland dissection of 100-300 Anopheles dirus mos-
quitoes that had been fed 14-16 days earlier on a
splenectomized donor monkey bearing the malarial
gametocytes in its peripheral blood.
Once the experimental monkeys were inoculated,
Giemsa-stained blood smears were prepared from per-
ipheral blood samples, and parasitaemia results were
determined daily from days 6 to 21 post-inoculation.
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was confirmed, and parasitaemia reached 5,000/μlf o r1 -
3 days per os (PO) as outlined in Table 1 and Addi-
tional File 1 and the remainder of this section. After
study day 21, if blood smears remained negative, they
were monitored three days per week for four weeks and
then twice weekly until 100 days post treatment, after
which the animals were considered to be radically
cured. In this model if treatment failure occurs, the ani-
mals relapse multiple times but in the interests of prac-
t i c a l i t yo n l yt h e1
st and 2
nd relapses are treated with
new anti-malarial compounds. Blood smears were moni-
tored daily for 21 days, then three times for four weeks,
and twice weekly until 100 days post treatment. At the
first and second relapses, monkeys were treated with
different combinations of study drug orally as appropri-
ate. They were administered a curative dose of standard
(expected to be 100% radically curative based on legacy
data) radical curative drug regimen, chloroquine/prima-
quine (10/1.78 mg/kg/day PO for seven days) as indi-
cated below at the third relapse or earlier if additional
study drugs were not given. Based on institutional legacy
data, this dose is known to be associated with 100%
radical cure.
Tafenoquine was obtained from GlaxoSmithKline
(Research Triangle Park, North Carolina). Primaquine
were obtained from the Walter Reed Army Institute of
Research (WRAIR) Chemical Inventory System. Both
compounds were administered as a suspension in 0.5%
hydroxyethylcellulose (HEC) vehicle. Chloroquine
diphosphate was obtained from Sigma and adminis-
tered in HEC. Pre-formulated quinine dichloride was
obtained from ANB Laboratories, Thailand, and was
administered intramuscularly. Artemether-lumefantrine
(Novartis) tablets were obtained commercially and
h o m o g e n i z e di na na p p r o p r i a t ev o l u m eo fH E Cf o r
oral administration. All oral drugs were dispensed by
disposable paediatric intra-gastric feeding tubes. Dur-
ing the period of drug administration and follow-up
the animals were housed in individual cages and regu-
lar enrichment items were offered. They were fed a
fixed ration of biscuits supplemented with enrichment
items including fresh fruits and seasonable vegetables
and routinely monitored up to three times daily for
any changes in activity, food consumption or other
clinical signs. The animals were weighed regularly dur-
ing the study period. Relevant clinical laboratory data
were generated prior to, daily through the initial treat-
ment period and weekly thereafter. Except where indi-
cated, all changes in body weight, general health or
clinical laboratory values were consistent with onset
and recovery from malaria infection, and are only
reported here where they appeared to be related to an
effect of study drugs.
Radical curative effects of tafenoquine at various doses
alone and in combination with chloroquine (Cohort 1)
This cohort objective was to identify the minimum dose
of tafenoquine required, alone, or in combination with
chloroquine, to radically cure P. cynomolgi malaria in
Rhesus monkeys. In this context, radical cure is defined
as the elimination of blood and liver stage parasites.
Groups of two monkeys received tafenoquine at doses
of 0.2, 0.6, 2 and 6 mg/kg/day × 3 days (monotherapy)
or tafenoquine at 0.06, 0.2, 0.6 and 2 mg/kg/day × 3
days combined with chloroquine at 16 mg/kg/day × 3
days, or tafenoquine at 12 mg/kg/day (single dose,
monotherapy), and one chloroquine control group at 16
mg/kg/day × 3 days.
The tafenoquine doses were chosen to evenly bracket
what were thought to be the ED50s of tafenoquine
alone and in combination with chloroquine based on
prior unpublished studies (these unpublished pilot
relapse studies were conducted with either 7-day chloro-
quine regimens, or regimens of tafenoquine adminis-
tered for one or seven days). The rationale for the
three-day regimen was as follows: The standard human
treatment dose for chloroquine is either 1500 mg over
three days or 25 mg/kg over three days [2,16]. The con-
version factor between humans and Rhesus monkeys for
chloroquine on a mg/kg basis based on similar efficacy
outcomes is approximately two [9]. The Rhesus monkey
chloroquine dose equivalent of a human treatment dose
is therefore approximately 50 mg/kg over three days.
Therefore a dose of 48 mg/kg in evenly divided doses
over three days was selected.
Table 1 Outcome of Chloroquine Treatments in Various Cohorts
Cohort# Chloroquine Regimen Relapse # Number of Cleared or Cured
Infections
Average Time To Relapse From Termination of
Treatment in Days
(+/- Standard Deviation)
2&3 24 mg/kg/day for
three days
Primary Treatment 4 of 4 9.8 +/- 1.7
1-3 24 mg/kg/day for
three days
Second Relapse 6 of 6 12.7 +/- 0.8
1-3 24 mg/kg/day for
three days + PQ
Second or Third
Relapse
9 of 9 radically cured No relapses
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dose of tafenoquine required to cure two of two mon-
keys. Treatment outcome of the monotherapy regimen
was defined as an early treatment failure (for blood schi-
zonticidal activity) if the parasitaemia did not decline
within the first 48 hours. In these instances, chloroquine
was subsequently administered at a dose of 16 mg/kg/
d a yf o rt h r e ed a y s .I nt h et a f e n o q u i n ea l o n eg r o u p s ,
relapses were treated with the next highest dose of tafe-
noquine. In the combination groups, relapses were trea-
ted with the same dose of tafenoquine and an adjusted
higher dose of chloroquine (24 mg/kg/day × 3 days, see
Table 1). Thereafter, additional relapses were treated
with the next highest dose of tafenoquine combined
with chloroquine at 24 mg/kg/day for three days.
Radical curative effects of tafenoquine combinations
(Cohort 2)
A number of different tafenoquine combination regi-
mens were evaluated in this cohort. Two groups of six
animals were given tafenoquine at a dose of 0.6 mg/kg/
day × 3 days combined with either chloroquine (24 mg/
kg/day × 3) or Coartem
® (artemether-lumefantrine 3/18
mg/kg twice per day for three days). A third group of
six monkeys were given a single dose of tafenoquine at
12 mg/kg in combination with mefloquine (30 mg/kg
administered as two spit doses, six hours apart). There
was one chloroquine control group (n = 2) at 24 mg/kg/
day × 3 days. A total mefloquine dose of 30 mg/kg was
selected on prior unpublished studies demonstrating its
efficacy against blood stage P. cynomolgi. Mefloquine
was administered as two equal 6-hour split doses for
logistical reasons and since split dosing is normal clini-
cal practice. A single dose of tafenoquine was used in
combination with a split, single day dose of mefloquine,
since at the time this study was conducted (2005), this
reflected a likely manner in which such a combination
would be used in a clinical setting. Coartem is a combi-
nation of artemether and lumefantrine (1:6 ratio). Six
doses of 12 hours apart are required to effect cure of
drug-resistant malaria [17]. Each dose consists of 80/480
mg artemether/lumefantrine (1.1-1.6/6.9-9.6 mg/kg for
50-70 kg person) for a total dose of 480/2880 mg (6.9-
9.6/41-58 mg/kg for a 50-70 kg person). The total cura-
tive dose of artemether against P. falciparum in owl
monkeys (Aotus sp.) is 24 mg/kg, 3.6 fold higher than
the total curative clinical dose. Therefore, in the absence
of efficacy data for artemether/lumefantrine in Rhesus
monkeys, a scaling factor of approximately two was
applied, since this is the usual difference between
humans and Rhesus monkeys for most blood schizonti-
cides [9]. Differences in the proportion of animals radi-
cally cured on the tafenoquine-mefloquine and
tafenoquine-Coartem regime n sv e r s u st h et a f e n o q u i n e -
chloroquine regimen were tested using Fisher’s Exact
test [18,19].
Anti-relapse activity of the minimum curative dose of
tafenoquine alone and with chloroquine (Cohort 3)
It was determined whether the efficacy of tafenoquine
(total dose of 1.8 mg/kg/day) against hypnozoites was
diminished in the absence of chloroquine, by eliminating
blood stage parasites prior to treatment. If this was the
case, it would imply that the presence of chloroquine
was required for tafenoquine to exert an antihypnozoite
effect at this dose. Six monkeys were given tafenoquine
(0.6 mg/kg/day × 3 days) alone or with chloroquine (24
mg/kg/day × 3 days) after a ten-day course of intramus-
cular quinine to eliminate blood stage parasites (loading
dose of 40 mg/kg base and followed by 20 mg/kg base
twice daily for ten days; total dose 420 mg/kg) shown in
pilot studies to eliminate blood stage parasites. All mon-
keys were negative by blood smear at the time of tafeno-
quine and tafenoquine/chloroquine dosing. The primary
endpoint of the study was the proportion of radical
cures observed in each group. Differences between
groups in terms of cure rates were determined using
Fisher’s Exact Test.
Tafenoquine, chloroquine and desethylchloroquine
plasma concentrations
Plasma samples were obtained from animals when feasi-
ble at 12, 24, 48, 60, 96 and 168 h (after the first dose)
in order to measure tafenoquine, chloroquine and
desethylchloroquine concentrations (additional samples
were not obtained in order to stay below the maximum
acceptable blood collection volume under the IACUC
protocol). Tafenoquine, chloroquine and desethylchloro-
quine concentrations were determined simultaneously
using HPLC-MS/MS after precipitation of plasma pro-
teins. The lower limits of quantification for all three
analytes was determined to be 10 ng/ml, using a 100 μl
plasma sample with an upper limit of quantitation of
1000 ng/ml. Plasma concentrations below the lowest
standard were considered to be unquantifiable. Quality
control (QC) samples prepared at three different analyte
concentrations and stored with the study samples, were
analyzed with each batch of samples. For the analysis to
be acceptable, no more than one-third of the QC results
were to deviate from the nominal concentration by
more than 15%, and at least 50% of the results from
each QC concentration had to be valid.
Measurement of methaemoglobin and other hematology
and blood chemistry endpoints
Changes in methaemoglobin levels were monitored using
a Radiometer OSM3 Hemoximeter as previously described
[20]. Methaemoglobin levels were determined on Days 0,
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Page 4 of 101, 2, 4 and 7 post-treatment. Other endpoints including
haematocrit, haemoglobin and complete blood counts
were determined on Day 0, daily from Days 6-90 and
twice weekly thereafter until conclusion of the experiment.
Changes in these endpoints were consistent with the
effects of malaria or recovery after drug treatment. No
drug-attributable changes in these endpoints (other than
methaemoglobin levels) were observed.
Results
Patency and relapse patterns amongst P. cynomolgi-
infected rhesus monkeys and utility of different
chloroquine regimens (Cohorts 1-3)
In the present series of three cohorts of monkeys, repre-
senting fifty four animals, patency was consistently
observed in all cases on Day 8.
In Cohort 1, one control monkey receiving 16 mg/kg/
day chloroquine experienced a delay in clearance of the
primary infection. At the time of the study, and in the
absence of chloroquine and desethyl-chloroquine con-
centrations which were determined later, the research
team was concerned that this might represent a failure
of the three day regimen. Therefore, the chloroquine
dose was increased to 24 mg/kg/day for three days from
16 mg/kg/day for three days in an attempt to suppress
delays in primary infection.
The 24 mg/kg/day × 3 regimen cleared parasitaemia
in all (n = 10) instances in which it was given to control
animals to treat relapses, and resulted in radical cure in
all (n = 9) instances in which it was administered in
combination with the standard curative seven days of
primaquine (at experiment termination, see Tables 1
and Additional File 1). A transient increase in parasitae-
mia prior to clearance was observed in a single instance.
Average times to the first and second relapses from the
l a s td a yo fc h l o r o q u i n et r e a t m e n tw e r e9 . 8+ / -1 . 7a n d
12.7 +/- 0.8 days (Table 1).
Radical curative effects of tafenoquine at various doses
alone and in combination with chloroquine (Cohort 1)
When given alone, the minimum dose of tafenoquine
required to radically cure 2 of 2 monkeys was 6 mg/kg/
day × 3 days (Additional File 1 and Table 2). When
given with chloroquine at 16 mg/kg/day × 3 days, the
minimum curative dose of tafenoquine was 0.6 mg/kg/
day × 3 days (Additional File 1 and Table 2). In mon-
keys given 0.6 mg/kg/day or 0.2 mg/kg/day tafenoquine
alone for three days, parasitaemia continued to rise after
administration of the drug indicating early blood-stage
treatment failure. Overall these data suggest that the
addition of chloroquine decreased the dose of tafeno-
quine required for radical cure by up to ten-fold.
There was an apparent pharmacodynamic interaction
between chloroquine and tafenoquine against blood
stage parasites. Tafenoquine administered alone exhib-
ited an apparent dose-related effect on parasite clear-
ance time (Figure 1). In monkeys given tafenoquine
monotherapy at doses of 2 and 6 mg/kg/day for three
days, average parasite clearance times were 4 and 3.5
days respectively (Figure 1). This compares to a parasite
clearance time of 3.5 days after a 1200 mg dose of tafe-
noquine against P. vivax i nh u m a n s[ 2 ] .L o w e rd o s e so f
tafenoquine alone did not clear parasitaemia in this
study. Chloroquine decreased parasite clearance time to
3 days when coadministered with tafenoquine at 2 mg/
kg/day for three days. At lower doses of tafenoquine,
chloroquine administered after initial tafenoquine failure
eventually resulted in radical cure. These data suggest
that chloroquine compensates for the poorer blood schi-
zonticidal effects of lower tafenoquine doses.
Chloroquine-cleared parasitaemia in the control mon-
k e y s( F i g u r e2 ) .H o w e v e r ,i no n em o n k e yat r a n s i e n t
increase in parasitaemia was observed after an initial
clearance prior to eventual clearance (Figure 2). Similar
transient increases were observed prior to eventual
clearance in some of the monkeys treated with chloro-
q u i n ea n d0 . 2o r0 . 0 6m g / k g / d a yo ft a f e n o q u i n ef o r
three days. These instances were interpreted to be
delays in the primary attack, emerging from late tissue
primary schizont development from delayed sporozoite
infection. In the control animal where such a transient
increase in parasitaemia occurred, the maximum
observed chloroquine and desethylchloroquine concen-
trations were 165 and 1140 ng/ml (516 and 3800 nM)
Table 2 Summary of Experimental Outcomes for Different TQ treatments in Cohort 1.
TQ Daily Dose TQ Alone TQ + CQ (16 mg/kg/day × 3)
(mg/kg/day × 3) #cured/not cured (%) #cured/not cured (%)
0.06 - 0/2 (0)
0.2 0/2 (0)* 0/2 (0)
0.6 0/2 (0)* 2/0 (100)
2 1/1 (50) 2/0 (100)
6 2/0 (100) -
* Early treatment failures
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parasitaemia were 65 and 95 ng/ml (204 and 315 nM)
respectively. In clinical use, peak chloroquine and
desethylchloroquine concentrations were 200-2000 and
90-1000 nM respectively [21], suggesting that in this
particular animal chloroquine and desethyl chloroquine
concentrations approximated those observed clinically.
In this cohort tafenoquine was also administered at a
single dose of 12 mg/kg PO. This regimen cleared para-
sitaemia in both monkeys (Additional File 1), and radi-
cally cured one of the two monkeys.
Radical curative effects of tafenoquine combinations
(Cohort 2)
The efficacy of two alternate regimens, mefloquine and
artemether-lumefantrine, in combination with tafeno-
quine were investigated. Five of five monkeys given tafe-
noquine-chloroquine (the sixth monkey was excluded
for reasons unrelated to study drug) and five of six
monkeys given tafenoquine-lumefantrine-artemether
were radically cured (Additional File 1). This difference
in cure rates was not significant (Fisher’se x a c tt e s t ,P =
0.54). A cure rate of 100% (6 of 6 monkeys) was
observed in the mefloquine-tafenoquine group (Addi-
tional File 1). Chloroquine alone (24 mg/kg/day for
three days) cleared (without transient increases) parasi-
taemia in both the control monkeys with subsequent
relapses.
Anti-relapse activity of the minimum curative dose of
tafenoquine alone and with chloroquine following
elimination of blood stages with quinine (Cohort 3)
Radical cures were achieved in 6 of 6 monkeys given
tafenoquine alone (0.6 mg/kg/day for three days) and 6
of 6 monkeys given tafenoquine at the same dose com-
bined with chloroquine (24 mg/kg/day for three days)
following quinine treatment. Thus, the efficacy of anti-
relapse activity of 1.8 mg/kg tafenoquine is not depen-
dent on co-administration with chloroquine.
Overall efficacy of tafenoquine at its minimum curative
dose
The overall efficacy of the presumed minimum curative
dose of tafenoquine is summarized in Table 3. When
the regimens are considered collectively, tafenoquine
was 100, 95 and 93% effective when administered alone
(after quinine pretreatment), combined with chloroquine
at low or high doses, or any blood schizontocidal,
respectively. Thirty three of thirty five treatments at this
dose level were successful, for an overall cure rate of
94%.
Methaemoglobin and tafenoquine plasma concentrations
Tafenoquine induced a dose-related increased in
methaemoglobin from baseline (data not shown). At the
highest dose of tafenoquine, methaemoglobin levels
peaked at 4.7% (Figure 3). In contrast in humans peak
methaemoglobin was 4.5% after a 600 mg dose and 9.0%
after an 1800 mg dose. Tafenoquine plasma-concentra-
tion time curves after administration of 0.6 mg/kg/day
(the minimum anti-relapse dose) for three days in n =
22 (for which data were available) under various condi-
tions are presented in Figure 4. Data were not able to
be generated for other doses of tafenoquine. The maxi-
mum observed tafenoquine concentrations clustered
narrowly between 20 and 84 ng/ml at 48-96 h post-dos-
ing. In two clinical P. vivax cases where tafenoquine was
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Figure 2 The course of infection in the two Cohort 2 control
monkeys given chloroquine alone at 16 mg/kg/base/day for
three days. For the purposes of illustration parasitaemia levels
falling below the limit of detection were arbitrarily assigned a value
of 1 parasite/μl. The transient increase in parasitaemia in one of the
monkeys after initial clearance is interpreted to be a delay in the
primary attack. The concentrations of chloroquine and
desethylchloroquine observed at the time of peak parasitaemia in
one monkey are indicated.
Figure 1 Course of parasitaemia in Cohort 2 monkeys given
tafenoquine (TQ) at 6 mg/kg base/day or 2 mg/kg base/day
alone or in combination with 16 mg/kg chloroquine base/day
for three days. The abbreviation DL refers to the detection limit of
parasitaemia by microscopy. For the purposes of illustration
parasitaemia levels falling below the limit of detection (approximate
location indicated by hashed line) were arbitrarily assigned a value
of 1 parasite/μl. Arrows indicate drug administration.
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Page 6 of 10given in a total dose of 1200 mg over three days and
resulted in radical cure, maximum observed plasma con-
centrations were 550 and 1100 ng/ml at 48 h [2].
Plasma tafenoquine levels were unavailable from the two
instances where relapses occurred at this dose. Plasma
tafenoquine levels were only available from one of two
animals (Cohort 2) in which this regimen failed to clear
blood stage parasites and required chloroquine rescue.
Tafenoquine levels were lower in this animal than the
others (Figure 4).
Table 3 Anti-relapse efficacy of a total tafenoquine dose 1.8 mg/kg (0.6 mg/kg/day for three days or 1.8 mg/kg once)
monotherapy or in combination with chloroquine and other blood stage regimens.
Treatment Cohort Notes of clarification Outcome
#cured/total (%)
TQ Alone*
Cohort 3 TQ given alone after quinine pretreatment 6/6 (100)
TQ + CQ 16
Cohort 1** CQ given sequentially after blood stage failure of first tafenoquine treatment regimen 2/2 (100)
Cohort 2 CQ + TQ given simultaneously for first treatment 2/2 (100)
TQ + CQ 24
Cohort 1 CQ given sequentially after blood stage failure of first relapse treatment 2/2 (100)
Cohort 1 Treatment of second relapse 1/2 (50)
Cohort 2 CQ + TQ given simultaneously for first treatment 5/5 (100)
Cohort 3 TQ given with CQ after quinine pretreatment to eliminate blood stage parasites 6/6 (100)
Unpublished data TQ given as a single dose for first treatment (data not shown) 2/2 (100)
TQ + Other Anti-malarials
Cohort 2 Simultaneous combination with artemether-lumefantrine for initial treatment 5/6 (83)
Unpublished data Simultaneous combination with atovaquone-proguanil for initial treatment (data not shown) 2/2 (100)
Total
Tafenoquine alone 6/6 (100)
TQ + CQ 20/21 (95)
TQ + all BS**All 27/29 (93)
TQ 33/35 (94)
* This refers to published data in which blood stage parasites were eliminated prior to tafenoquine or tafenoquine/chloroquine treatment. ** These are monkeys
(Table 1) which were treated with chloroquine after tafenoquine monotherapy failed to clear blood stage parasites. For the purposes of the anti-relapse
endpoint, these monkeys were considered to have been given a combination regimen. ** All blood schizonticidal drugs.
Figure 3 Methaemoglobin levels in Rhesus monkeys given a
total dose of 18 mg/kg (6 mg/kg/day × 3) tafenoquine and
human subjects given chloroquine (CQ), a single 600 mg or
three 600 mg doses of tafenoquine (TQ). Clinical data are from
Walsh et al (2004).
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Figure 4 Tafenoquine plasma concentration time curves for 22
individual monkeys given tafenoquine at a dose of 0.6 mg/kg/
day for three days under various conditions. No other data for
tafenoquine plasma levels for tafenoquine were available at any
other dose. The arrows indicate the times of dosing. Maximum
observed tafenoquine plasma concentrations were between 20-85
ng/ml between 48 and 96 h after dosing. Data were unavailable for
the two monkeys that relapsed at this dose. Data (red circles and
solid line) were available for only one of two monkeys in Cohort 2
where this dose given alone for radical cure failed in both animals,
and chloroquine rescue was required.
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In the present study, a modified Rhesus monkey-P.
cynomolgi model was utilized to evaluate the radical
curative efficacy of tafenoquine combined with various
blood schizonticidal drugs administered at human
equivalent doses. The data show that tafenoquine, when
combined with chloroquine and other drugs is an effec-
tive radical curative agent against P. cynomolgi malaria
at much lower doses than those used in prior P. vivax
clinical trials. In the discussion that follows, some of the
methodologic aspects of this animal model are
addressed together with potential relevance the data in
terms of future clinical use of tafenoquine.
In the present model application, some refinements to
the original methods of Schmidt et al [9] were made.
These involved the methods of preparation of sporo-
zoites prior to inoculation, the use of standard inocula-
tion dose and the use of three-day chloroquine
regimens. The more refined methods used for sporo-
zoite processing are likely to have increased the viability
of the inoculums given. This may explain the greater
variability in the time to patency observed by Schmidt et
al [9] compared to this study (average time to patency
in days +/- standard deviation of 8.4 +/- 0.6 days, n =
538 v 8.0 +/- 0.0 days, n = 54). The utility of the three-
day chloroquine regimens is evidenced by 100% clear-
ance in all instances (n = 11) when either regimen was
used to treat relapses in control monkeys, and radical
cure in all (total n = 30) instances but one in which
either of the three-day chloroquine regimens were given
in combination with effective regimens of tafenoquine
or primaquine for radical cure. These observations sug-
gest that the three-day chloroquine regimens can be
used in place of seven-day regimens.
Occasional increases in parasitaemia prior to clearance
after treatment with the three-day chloroquine regimens
were observed. When this first occurred in the Cohort 1
controls, the research team was concerned that these
may have been failures, so the chloroquine dose was
increased. However other data suggest this is a feature
of the animal model itself. Usually, when chloroquine is
given as a seven-day regimen, a dose of 10 mg/kg/day is
the usual choice. This is based on the observation that
lower doses are sub-curative [13]. However, in some
instances where this regimen is administered for the pri-
mary treatment, parasitaemia is not initially cleared. In
such cases the course of treatment is extended for 2-4
days, but sometimes up to 7 additional days until blood
stage parasites are cleared [14]. This phenomenon
occurs periodically in some experiments and is presum-
ably related to the large sporozoite inoculums given.
Since effective levels of chloroquine and desethylchloro-
quine were present in the two control monkeys given 16
mg/kg/day for three days it is likely that the transient
increase in parasitaemia observed in one of these mon-
keys represents the normal pattern of variability in the
model, rather than a failure of the three-day chloroquine
regimen.
The minimum dose of tafenoquine required for pre-
vention of P. vivax relapses in humans has not been
definitely established, despite the execution of two clini-
cal studies to determine this. Walsh et al [22,23] evalu-
ated the protective efficacy of tafenoquine relative to
chloroquine alone, and when administered sequentially
following treatment of symptomatic P. vivax malaria
with chloroquine (Table 4). Several factors suggest cau-
tion should be exercised when interpreting these human
data. The group sizes were small, and protective efficacy
calculations were made based on single relapses. While
care was taken to prevent re-infection, these cannot be
ruled out in the endemic area situation. No dose-effect
relationship is clear, and the confidence intervals across
the treatment groups were wide and overlapped. The
nature of the relapses (delayed as is the case for regional
‘primaquine-tolerant P. vivax malaria’ or associated with
vomiting) means that they cannot be unequivocally
attributed to the failure of tafenoquine. All that can be
stated definitively is that total doses of tafenoquine
greater than or equal to 500 mg appear to prevent
relapses in most instances. In the same studies, prima-
quine (15 mg/day) was administered for 14 days in a
controlled setting yielding a protective efficacy of 80%.
Table 4 Anti-relapse efficacy of tafenoquine in various regimens and primaquine in human cases compared to
chloroquine in Thailand (from Walsh et al 1999; 2004).
Drug Dose Total Dose #Subjects #Relapses Efficacy (% +/- 95% CI) Comment on Relapse
Tafenoquine 500 mg 500 9 1 87 (-37-100) Relapse delayed
Tafenoquine 600 mg 600 18 1 96 (67-99) Vomiting
Tafenoquine 600 mg × 3 1800 19 0 100 (78-100)
Tafenoquine 300 mg × 7 2100 19 0 100 (78-100)
Tafenoquine 300 mg × 7 2100 15 0 100 (24-100)
Tafenoquine 500 mg × 3, repeated 3000 11 1 87 (-34-100) Relapse delayed
Primaquine 15 mg × 14 12 3 80 (15-97)
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anti-relapse efficacy would still be useful, and would
likely have greater effectiveness in the field due to the
much more convenient dosing regimen. The available
clinical data are not helpful in determining what this
dose might be.
In the present studies, it was shown that when tafeno-
quine is combined with chloroquine, the doses of tafe-
noquine (total minimum curative dose of 1.8 mg/kg)
required for radical cure can be reduced by up to ten-
fold compared to administration of the drug alone (total
MCD 18 mg/kg) in a relapsing malaria model. At such a
low dose of tafenoquine, plasma levels of tafenoquine
were substantially lower than those observed after a
1,200 mg dose in humans (Figure 4,[2]). Based on
approximately equivalent methaemoglobin responses,
t h eR h e s u sm o n k e yM C Do f1 8m g / k gt a f e n o q u i n ei s
likely equivalent to a dose of 600 mg in humans [23].
Based on approximately equivalent parasite clearance
times, the Rhesus monkey MCD of tafenoquine of 18
mg/kg when administered alone is likely equivalent to a
dose of 1,200 mg in humans [2]. These data provide the
basis for proposing the hypothesis that much lower tafe-
noquine doses may impart substantial anti-relapse activ-
ity in future clinical studies. Administration of such low
doses may be required if the liability of haemolytic toxi-
city in G6PD deficiency humans is to be mitigated.
This dose reduction does not appear to specifically
require chloroquine. Although one relapse/recrudes-
cence was observed in the artemether-lumefantrine
group, no statistical difference in efficacy was shown
between tafenoquine-chloroquine and tafenoquine-arte-
mether-lumefantrine combination regimens (both with
tafenoquine at a total dose of 1.8 mg/kg). The single
failure in the tafenoquine-artemether-lumefantrine
group was attributable to chance, since overall the
observed probability of a relapse with 1.8 mg/kg tafeno-
q u i n ei sa p p r o x i m a t e l y6 %( T a b l e4 ) .A tt h es a m ed o s e
of tafenoquine, it was also shown that there was no dif-
ference in anti-relapse efficacy when the compound was
administered alone or with chloroquine after quinine
pretreatment to eliminate blood stage parasites. This
observation and the approximate equivalence of the
tafenoquine-chloroquine and tafenoquine-artemether-
lumefantrine regimens suggest that tafenoquine can be
combined with any effective blood schizonticidal drug.
Tafenoquine at a single dose of 12 mg/kg PO cured
only one of two animals when administered as mono-
therapy, a failure we interpret to be a recrudescence
rather than a relapse, since much lower doses were
effective for anti-relapse therapy. However, the same
dose of tafenoquine was very effective when combined
with mefloquine (six of six animals cured). The effec-
tiveness of the combination demonstrates the potential
utility of single day tafenoquine combination regimen,
although the use of therapeutic level doses of meflo-
quine would require very careful thought, and would
only be justifiable in the appropriate risk-benefit context
(i.e. elimination attempts).
The ability to lower tafenoquine doses with a partner
blood schizonticide comes at a cost. It was clear in
Cohort 1 monkeys that chloroquine improved parasite
clearance times, and was required for adequate elimina-
tion of blood stage parasites at lower tafenoquine doses
lacking useful blood schizonticidal activity. Thus, if
chloroquine was proposed as the partner drug, and the
tafenoquine dose was lowered to mitigate the risk of
haemolytic toxicity (and, therefore, its blood schizonto-
cidal effect was reduced), it is possible that any putative
synergy of tafenoquine and chloroquine against the
blood stages of chloroquine-resistant P. vivax would be
lost. The alternative would be to employ an alternate
blood-stage regimen that is fully effective in its own
right against blood stage P. vivax (and preferably also P.
falciparum). Artemether-lumefantrine would serve this
purpose as would other drugs in clinical use and devel-
opment (e.g. piperaquine-dihydroartemisinin). Alving et
al [24] showed that cure rates of sub-curative doses of
primaquine could be increased if combined with chloro-
quine or quinine. This is also a possibility with tafeno-
quine, and was a question left incompletely addressed
by this study. If this does occur it is insufficient to result
in a substantial reduction in the dose required for anti-
relapse efficacy since a dose of 0.2 mg/kg/day of tafeno-
quine for three days combined with chloroquine is not
as efficacious as 0.6 mg/kg/day tafenoquine alone for
three days. These observations should be considered
carefully by clinicians planning future tafenoquine-P.
vivax clinical trials.
Additional material
Additional file 1: Summary of treatment outcomes in three cohorts
of Rhesus monkeys dosed with tafenoquine and other antimalarials.
The file provides a summary of treatment outcomes in three cohorts of
Rhesus monkeys dosed with tafenoquine and other antimalarials.
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